Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma.
Adv Respir Med
; 91(4): 288-300, 2023 Jul 04.
Article
in En
| MEDLINE
| ID: mdl-37489386
ABSTRACT
Long-acting muscarinic antagonists (LAMAs) are a class of inhalers that has recently been included as add-on therapy in the GINA guidelines, either in a single inhaler device with inhaled corticosteroids plus long-acting ß2-agonists (ICS + LABA) (closed triple inhaler therapy) or in a separate one (open triple inhaler therapy). This review summarizes the existing evidence on the addition of LAMAs in patients with persistently uncontrolled asthma despite ICS + LABA treatment based on clinical efficacy in the reduction of asthma symptoms and exacerbations, the improvement in lung function, and its safety profile.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Asthma
/
Adrenergic beta-2 Receptor Agonists
Type of study:
Guideline
Limits:
Humans
Language:
En
Journal:
Adv Respir Med
Year:
2023
Type:
Article
Affiliation country:
Greece